Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1990 1
1991 2
1992 1
1993 2
1997 2
1998 2
1999 2
2000 1
2001 1
2002 2
2004 1
2005 1
2006 1
2007 2
2008 2
2009 2
2010 4
2011 5
2012 3
2013 3
2014 4
2015 6
2016 5
2017 1
2018 3
2019 2
2020 2
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Management of Borderline Resectable Pancreatic Cancer.
Toesca DAS, Koong AJ, Poultsides GA, Visser BC, Haraldsdottir S, Koong AC, Chang DT. Toesca DAS, et al. Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1155-1174. doi: 10.1016/j.ijrobp.2017.12.287. Int J Radiat Oncol Biol Phys. 2018. PMID: 29722658 Review.
Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrated that this intermediate category carries a particular prognosis that is in between resectable and unresectable disease. In order to …
Although there is a lack of consensus regarding the appropriate definition of what constitutes a BR pancreatic tumor, it has been demonstrat …
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
Jang JK, Byun JH, Kang JH, Son JH, Kim JH, Lee SS, Kim HJ, Yoo C, Kim KP, Hong SM, Seo DW, Kim SC, Lee MG. Jang JK, et al. Eur Radiol. 2021 Feb;31(2):813-823. doi: 10.1007/s00330-020-07188-8. Epub 2020 Aug 26. Eur Radiol. 2021. PMID: 32845389
OBJECTIVES: We aimed to assess the ability of CT-determined resectability, as defined by a recent version of NCCN criteria, and associated CT findings to predict margin-negative (R0) resection in patients with PDAC after neoadjuvant FOLFIRINOX chemotherapy. ...CONCLUSION: …
OBJECTIVES: We aimed to assess the ability of CT-determined resectability, as defined by a recent version of NCCN criteria, and associated C …
Retinoids in pancreatic cancer.
Riecken EO, Rosewicz S. Riecken EO, et al. Ann Oncol. 1999;10 Suppl 4:197-200. Ann Oncol. 1999. PMID: 10436821 Review.
Prognosis of advanced, unresectable pancreatic adenocarcinoma remains dismal and has not significantly improved over the past 20 years. ...
Prognosis of advanced, unresectable pancreatic adenocarcinoma remains dismal and has not significantly improved over the past 20 year …
Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples.
Redegalli M, Grassini G, Magliacane G, Pecciarini L, Schiavo Lena M, Smart CE, Johnston RL, Waddell N, Maestro R, Macchini M, Orsi G, Petrone MC, Rossi G, Balzano G, Falconi M, Arcidiacono PG, Reni M, Doglioni C, Cangi MG. Redegalli M, et al. Clin Gastroenterol Hepatol. 2023 Oct;21(11):2825-2833. doi: 10.1016/j.cgh.2022.10.014. Epub 2022 Oct 22. Clin Gastroenterol Hepatol. 2023. PMID: 36280101
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease, for which it is crucial to promptly detect actionable and prognostic alterations to drive specific therapeutic decisions, regardless of tumor resectability status. ...
BACKGROUND & AIMS: Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive disease, for which it is crucial to promptly detect ac …
Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
Insulander J, Sanjeevi S, Haghighi M, Ivanics T, Analatos A, Lundell L, Del Chiaro M, Andrén-Sandberg Å, Ansorge C. Insulander J, et al. Br J Surg. 2016 Aug;103(9):1200-8. doi: 10.1002/bjs.10190. Epub 2016 Jun 2. Br J Surg. 2016. PMID: 27250937
The aim of this study was to compare PDB with exploratory laparotomy alone in terms of impact on postoperative course, chemotherapy and overall survival. METHODS: This retrospective observational cohort study (2004-2013) was conducted using a prospective institutional data …
The aim of this study was to compare PDB with exploratory laparotomy alone in terms of impact on postoperative course, chemotherapy a …
Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Ogawa K, Ito Y, Hirokawa N, Shibuya K, Kokubo M, Ogo E, Shibuya H, Saito T, Onishi H, Karasawa K, Nemoto K, Nishimura Y; Japanese Radiation Oncology Study Group Working Subgroup of Gastrointestinal Cancers. Ogawa K, et al. Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):559-65. doi: 10.1016/j.ijrobp.2011.07.013. Epub 2011 Oct 20. Int J Radiat Oncol Biol Phys. 2012. PMID: 22019243
On multivariate analysis, AC use and clinical T stage were significant prognostic factors for OS. CONCLUSIONS: CCRT using GEM yields a relatively favorable LC rate for unresectable pancreatic adenocarcinoma, and CCRT with AC conferred a survival benefit compared to CCRT wi …
On multivariate analysis, AC use and clinical T stage were significant prognostic factors for OS. CONCLUSIONS: CCRT using GEM yields …
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Ali CW, Kaye TF, Adamson DJ, Tait IS, Polignano FM, Highley MS. Ali CW, et al. J Gastrointest Cancer. 2007;38(2-4):108-14. doi: 10.1007/s12029-008-9019-x. J Gastrointest Cancer. 2007. PMID: 19089662
CONCLUSIONS: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and cholangiocarcinoma. ...
CONCLUSIONS: The CA 19-9 concentration has a valuable role in predicting outcome in patients with pancreatic adenocarcinoma and chola …
Palliation of biliary and duodenal obstruction in patients with unresectable pancreatic cancer: endoscopy or surgery?
Maire F, Sauvanet A. Maire F, et al. J Visc Surg. 2013 Jun;150(3 Suppl):S27-31. doi: 10.1016/j.jviscsurg.2013.03.005. Epub 2013 Apr 15. J Visc Surg. 2013. PMID: 23597937 Free article. Review.
Patients with unresectable pancreatic adenocarcinoma often develop biliary and/or duodenal obstruction during the course of their disease. Jaundice, pruritis, nausea and vomiting impact negatively on the quality of life and chemotherapy must often be withheld until these s …
Patients with unresectable pancreatic adenocarcinoma often develop biliary and/or duodenal obstruction during the course of their dis …
56 results